Major developments in the treatment of multiple myeloma (MM) over the past decade have
led to a continued improvement in survival. Significant progress has been made with deeper …

Background In patients with newly diagnosed multiple myeloma, the effect of adding
autologous stem-cell transplantation (ASCT) to triplet therapy (lenalidomide, bortezomib …

The therapeutic landscape in multiple myeloma (MM) has changed dramatically over the last
2 decades. With the introduction of novel immunotherapies, patients with MM can expect …

PURPOSE The MASTER trial combined daratumumab, carfilzomib, lenalidomide, and
dexamethasone (Dara-KRd) in newly diagnosed multiple myeloma (NDMM), using minimal …

The NCCN Guidelines for Multiple Myeloma provide recommendations for diagnosis, initial
workup, treatment, follow-up, and supportive care for patients with various plasma cell …

Despite improving outcomes, 40% of patients with newly diagnosed multiple myeloma
treated with regimens containing daratumumab, a CD38-targeted monoclonal antibody …

Background For patients with newly diagnosed multiple myeloma, reaching minimal residual
disease (MRD) negativity after treatment is associated with improved outcomes; however …

PURPOSE The GMMG-CONCEPT trial investigated isatuximab, carfilzomib, lenalidomide,
and dexamethasone (Isa-KRd) in transplant-eligible (TE) and transplant-noneligible (TNE) …

The continuous implementation of novel agents in the treatment of multiple myeloma (MM)
has led to significant improvement in survival. Especially the addition of monoclonal …

PURPOSE Minimal residual disease (MRD) can predict outcomes in patients with multiple
myeloma, but limited data are available on the prognostic impact of MRD when assessed at …